Disclosures for "Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe"
-
Dr. Hargraves has received personal compensation for serving as an employee of argenx. Dr. Hargraves has stock in argenx.
-
Mr. Allosery has received personal compensation for serving as an employee of argenx. Mr. Allosery has stock in argenx.
-
Author has nothing to disclose
-
Dr. De Muynck has received personal compensation for serving as an employee of argenx.
-
The institution of Mr. Noukens has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx.